Alfonso Sa
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.
Journal: ESMO open
Published: November 25, 2025
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis.
Journal: Cancer treatment reviews
Published: October 05, 2025
Understanding the Toxicity Profile of Approved ADCs.
Journal: Pharmaceutics
Published: January 11, 2025
Understanding the Preclinical Efficacy of Antibody-Drug Conjugates.
Journal: International journal of molecular sciences
Published: November 12, 2024
Targeting of Non-Classical Human Leukocyte Antigens as Novel Therapeutic Strategies in Cancer.
Journal: Cancers
Published: November 10, 2024
Molecular Profiling of Endocrine Resistance in HR+/HER2-Metastatic Breast Cancer: Insights from Extracellular Vesicles-Derived DNA and ctDNA in Liquid Biopsies.
Journal: International journal of molecular sciences
Published: October 31, 2024
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
Journal: Breast cancer research and treatment
Published: March 01, 2024
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.
Journal: Journal of hematology & oncology
Published: October 17, 2023
Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study.
Journal: Cancers
Published: June 07, 2023
Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates.
Journal: Clinical and translational medicine
Published: March 03, 2023
Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor.
Journal: Frontiers in oncology
Published: July 18, 2022
Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report.
Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report.
Journal: World journal of surgical oncology
Published: July 15, 2021
Last Updated: 09/26/2026